Advertisement

Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system

  • M. P. Ballester
  • D. Marti-AguadoEmail author
  • M. Fullana
  • M. M. Bosca-Watts
  • J. Tosca
  • E. Romero
  • A. Sanchez
  • P. Navarro-Cortes
  • R. Anton
  • F. Mora
  • M. Minguez
Original Article
  • 24 Downloads

Abstract

Background and objective

To determine the impact of non-adherence to 5-Aminosalicylates (5-ASA) on the risk of flares and to identify risk factors of non-adherence.

Methods

Observational, cohort study of ulcerative colitis (UC) patients in clinical remission at least 6 months on 5-ASA monotherapy maintenance prescribed by an electronic management program. Adherence was considered when 80% of the prescribed 5-ASA had been dispensed at the pharmacy. The study analyzed the existence and degree of 5-ASA adherence, disease course, UC phenotypic expression, and 5-ASA dose and regimen, and consumption of non-UC chronic drugs during 2-year follow-up.

Results

The study included 274 patients, 49% males with a median age of 38 (27–49) years old. Overall, 41% of patients were non-adherent to 5-ASA. Risk of flares was reduced in the adherent group (36% vs 54%; OR = 0,484; p = 0,004), mainly the mild ones (26% vs 38%; OR = 0,559; p = 0,031). Non-adherence was associated with younger age at diagnosis (32 (26–45) vs 41.5 (21–50), p = 0.000) and no-consumption of other chronic treatments (1.1 vs 2.1; OR = 1709; p = 0,048).

Conclusion

Non-adherence to 5-ASA evaluated by the pharmaceutical management system was at 41% with a higher risk of relapse. Younger patients and patients who do not receive non-UC chronic treatments showed lower adherence rate.

Keywords

Colitis, ulcerative Aminosalicylic acids Treatment adherence and compliance Treatment outcome Symptom flare-up 

Notes

Authors’ contributions

Conception and design of the study: Ballester MP, Martí-Aguado D, Fullana M, Bosca-Watts MM, and Minguez M

Acquisition of data: Ballester MP, Martí-Aguado D, Fullana M, Romero E, Sanchez A, Navarro P, and Anton R

Analysis and interpretation of data: Ballester MP, Martí-Aguado D, Bosca-Watts MM, Tosca J, and Minguez M

Manuscript writing: Ballester MP, Martí-Aguado D, Bosca-Watts MM, Tosca J, Mora F, and Minguez M

All listed authors approved the final version.

Compliance with ethical standards

Conflict of interest

M. Minguez has served as a speaker, a consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Janssen, Shire Pharmaceuticals, Allergan.

M.M. Bosca-Watts declares educational activities, research projects, scientific meetings, and advisory boards sponsored by MSD, Ferring, Abbvie, Janssen, and Takeda.

Informed consent statement

All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Institutional review board approval

The study was reviewed and approved by the University Clinic Hospital of Valencia, Institutional Review Board.

References

  1. 1.
    Hardbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, European Crohn’s and Colitis Organisation (ECCO) (2017) Third European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn Colitis 11:769–784.  https://doi.org/10.1093/ecco-jcc/jjx009 CrossRefGoogle Scholar
  2. 2.
    Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O’Morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D’Haens G (2011) Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 34:113–124.  https://doi.org/10.1111/j.1365-2036.2011.04701.x CrossRefGoogle Scholar
  3. 3.
    Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, Moayyedi P (2011) Efficacy of 5-ASA in UC: a meta-analysis. Am J Gastroenterol 106:601–616.  https://doi.org/10.1038/ajg.2011.67. CrossRefGoogle Scholar
  4. 4.
    Wang Y, Parker CE, Feagan BG, MacDonald JK (2016) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4:CD000543.  https://doi.org/10.1002/14651858.CD000544.pub4. Google Scholar
  5. 5.
    Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345–1353CrossRefGoogle Scholar
  6. 6.
    Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497.  https://doi.org/10.1056/NEJMra050100 CrossRefGoogle Scholar
  7. 7.
    Cerveny P, Bortlik M, Vlcek J, Kubena A, Lukás M (2007) Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 13:1244–1249.  https://doi.org/10.1016/j.crohns.2007.08.002. CrossRefGoogle Scholar
  8. 8.
    Bager P, Julsgaard M, Vesteergard T, Christensen LA, Dahlerup JF (2016) Adherence and quality of care in IBD. Scand J Gastroenterol 51(11):1326–1331.  https://doi.org/10.1080/00365521.2016.1195870 CrossRefGoogle Scholar
  9. 9.
    Kane S, Huo D, Aikens J, Hanauer S (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114:39–43CrossRefGoogle Scholar
  10. 10.
    Kawakami A, Tanaka M, Nishigaki M, Naganuma M, Iwao Y, Hibi T, Sanada H, Yamamoto-Mitani N, Kazuma K (2013) Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 48:1006–1015.  https://doi.org/10.1007/s00535-012-0721-x CrossRefGoogle Scholar
  11. 11.
    Higgins P, Rubin DT, Kaulback K, Schoendfield PS, Kane SV (2008) Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and costs of ulcerative colitis flares. Aliment Pharmacol Ther 29:247–257.  https://doi.org/10.1111/j.1365-2036.2008.03865.x. CrossRefGoogle Scholar
  12. 12.
    Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel-Wood M (2012) Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-years retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 36:755–764.  https://doi.org/10.1111/apt.12013 CrossRefGoogle Scholar
  13. 13.
    Van Staa TP, Card T, Logan RF, Leufkens HG (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54:1573–1578CrossRefGoogle Scholar
  14. 14.
    Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD (2012) Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol 12:132.  https://doi.org/10.1186/1471-230X-12-132 CrossRefGoogle Scholar
  15. 15.
    Kane S, Shaya F (2008) Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 53:1020–2024CrossRefGoogle Scholar
  16. 16.
    Khan N, Abbas AM, Koleva YN, Bazzano LA (2013) Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. Inflamm Bowel Dis 19(6):1123–1129.  https://doi.org/10.1097/MIB.0b013e318280b1b8 CrossRefGoogle Scholar
  17. 17.
    Bermejo F, López-San Román A, Algaba A, Guerra I, Valer P, García-Garzón S, Piqueras B, Villa C, Bermejo A, Rodríguez-Agulló JL (2010) Factors that modify therapy adherence in patients with inflammatory bowel disease. J Crohn Colitis 4:422–426.  https://doi.org/10.1016/j.crohns.2010.01.005 CrossRefGoogle Scholar
  18. 18.
    Algaba A, Guerra I, Garcia Garcia de Pareces A, Hernández Tejero M, Ferre C, Bonillo D, Aguilera L, López-Sanromán A, Bermejo F (2017) What is the real life manteinance mesalazine dose in ulcerative colitis? Rev Esp Enferm Dig 109(2):114–121.  https://doi.org/10.17235/reed.2016.4620/2016. Google Scholar
  19. 19.
    Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, McPhail C, Deering K, Bernstein CN (2007) Predictor of medication adherence in inflammatory bowel disease. Am J Gastroenterol 102(7):1417–1426CrossRefGoogle Scholar
  20. 20.
    Li W, Zhang ZM, Jiang XL (2016) Once daily versus multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis. Color Dis 18(7):0214–0223.  https://doi.org/10.1111/codi.13393 CrossRefGoogle Scholar
  21. 21.
    Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl):5A–36ACrossRefGoogle Scholar
  22. 22.
    Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J (2013) Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. Gastroenterol Hepatol 36:1–47.  https://doi.org/10.1016/j.gastrohep.2012.09.006 CrossRefGoogle Scholar
  23. 23.
    Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ (2018) No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol.  https://doi.org/10.1038/s41395-018-0144-2
  24. 24.
    Jackson CA, Clatworthy J, Robinson A, Horne R (2010) Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 105:525–539.  https://doi.org/10.1038/ajg.2009.685 CrossRefGoogle Scholar
  25. 25.
    Keil R, Keil R, Wasserbauer M, Zádorová Z, Kojecký V, Hlava Š, Št'ovíček J, Chudý J, Roznětinská M, Drábek J, Kubišová N, Lochmannová J (2018) Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol 53(4):459–465.  https://doi.org/10.1080/00365521.2018.1451915 CrossRefGoogle Scholar
  26. 26.
    Kane SV, Robinson A (2010) Review article: understanding adherence to medication in ulcerative colitis – innovative thinking and evolving concepts. Aliment Pharmacol Ther 32(9):1051–1058.  https://doi.org/10.1111/j.1365-2036.2010.04445.x CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • M. P. Ballester
    • 1
  • D. Marti-Aguado
    • 1
    Email author
  • M. Fullana
    • 2
  • M. M. Bosca-Watts
    • 1
  • J. Tosca
    • 1
  • E. Romero
    • 1
  • A. Sanchez
    • 1
  • P. Navarro-Cortes
    • 1
  • R. Anton
    • 1
  • F. Mora
    • 1
    • 2
  • M. Minguez
    • 1
    • 2
  1. 1.IBD Unit, Digestive Disease Department, University Clinic Hospital of ValenciaUniversity of ValenciaValenciaSpain
  2. 2.University of ValenciaValenciaSpain

Personalised recommendations